Literature DB >> 11698305

Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice.

S Maury1, B Salomon, D Klatzmann, J L Cohen.   

Abstract

After non-T-cell-depleted allogeneic hematopoietic stem cell transplantation (HSCT), both alloreactive and homeostatic signals drive proliferation of donor T cells. Host-reactive donor T cells, which proliferate on alloantigen stimulation, are responsible for the life-threatening graft-versus-host disease. Non-host-reactive donor T cells, which proliferate in response to homeostatic signals, contribute to the beneficial peripheral T-cell reconstitution. The elimination of alloreactive T cells is a major therapeutic challenge for HSCT and would greatly benefit from their specific identification. After T-cell transfer in lymphopenic recipients, the present results show that alloreactive T cells rapidly divided; up-regulated CD69, CD25, and CD4 molecules; and down-regulated CD62L. In contrast, nonalloreactive T cells started to divide later and did not up-regulate CD69, CD25, and CD4. Thus, these 2 cell populations can be effectively discriminated. This should facilitate the specific depletion of alloreactive T cells in allogeneic HSCT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698305     DOI: 10.1182/blood.v98.10.3156

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

2.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

Authors:  Damien Bresson; Lisa Togher; Evelyn Rodrigo; Yali Chen; Jeffrey A Bluestone; Kevan C Herold; Matthias von Herrath
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

3.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

Authors:  Ken-ichi Matsuoka; Haesook T Kim; Sean McDonough; Gregory Bascug; Ben Warshauer; John Koreth; Corey Cutler; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

4.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.

Authors:  Aurélie Trenado; Frédéric Charlotte; Sylvain Fisson; Micael Yagello; David Klatzmann; Benoit L Salomon; José L Cohen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

5.  An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues.

Authors:  Ronjon Chakraverty; Daniel Côté; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Teviah Sachs; Costas M Pitsillides; Roderick Bronson; Terry Means; Charles Lin; Megan Sykes
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

6.  In vivo activation of transferred regulatory T cells specific for third-party exogenous antigen controls GVH disease in mice.

Authors:  Gaëlle H Martin; Sylvie Grégoire; Dan A Landau; Caroline Pilon; Yenkel Grinberg-Bleyer; Frédéric Charlotte; Jean-Pierre Mège; Lucienne Chatenoud; Benoît L Salomon; José L Cohen
Journal:  Eur J Immunol       Date:  2013-07-09       Impact factor: 5.532

7.  Photoconversion of Alloreactive T Cells in Murine Peyer's Patches During Acute Graft-Versus-Host Disease: Tracking the Homing Route of Highly Proliferative Cells In Vivo.

Authors:  Katja J Jarick; Zeinab Mokhtari; Lukas Scheller; Julia Hartweg; Sina Thusek; Duc-Dung Le; Maria Ranecky; Haroon Shaikh; Musga Qureischi; Katrin G Heinze; Andreas Beilhack
Journal:  Front Immunol       Date:  2018-06-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.